Clinical Review 145: Pleiotropic Effects of Statins: Lipid Reduction and Beyond

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 2002 Apr 5

PMID 11932263

Citations 90

Authors

S I McFarlane

R Muniyappa

R Francisco

J R Sowers

Affiliations

Soon will be listed here.

Abstract

There is accumulating evidence that statins have beneficial effects that are independent of their classical actions on lipoproteins. These effects include reductions in inflammation in the vasculature, kidney, and bone. Potential beneficial effects of these agents include enhancement of nitric oxide production in vasculature and the kidney. These agents appear to reduce bone fractures and may improve insulin sensitivity and reduce the likelihood of persons progressing from impaired glucose tolerance to type II diabetes. Potential beneficial pleiotropic effects of statins are covered in this review.

Citing Articles

The Impact of Atorvastatin Treatment on the Distribution of Low-Density Lipoprotein Subfractions and the Level of Vitamin D in Patients After Acute Myocardial Infarction: Preliminary Findings.

Sygitowicz G, Sitkiewicz D, Wrzosek K, Dluzniewski M Int J Mol Sci. 2024; 25(20).

PMID: 39457047 PMC: 11508669. DOI: 10.3390/ijms252011264.

Screening of Lipid-Reducing Activity and Cytotoxicity of the Exometabolome from Cyanobacteria.

Luz R, Cordeiro R, Goncalves V, Vasconcelos V, Urbatzka R Mar Drugs. 2024; 22(9).

PMID: 39330293 PMC: 11433081. DOI: 10.3390/md22090412.

Anti-Inflammatory Effect of Atorvastatin and Rosuvastatin on Monosodium Urate-Induced Inflammation through IL-37/Smad3-Complex Activation in an In Vitro Study Using THP-1 Macrophages.

Kim S, Choe J, Kim J, Park K, Kim B Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065733 PMC: 11280082. DOI: 10.3390/ph17070883.

Overview of clinical status, treatment, and long-term outcomes of pediatric autosomal-dominant polycystic kidney disease: a nationwide survey in Taiwan.

Chin C, Huang W, Wang J, Liou J, Hsu H, Chen M Sci Rep. 2024; 14(1):16280.

PMID: 39009643 PMC: 11251175. DOI: 10.1038/s41598-024-67250-z.

Dysregulated cellular metabolism in atherosclerosis: mediators and therapeutic opportunities.

Stroope C, Nettersheim F, Coon B, Finney A, Schwartz M, Ley K Nat Metab. 2024; 6(4):617-638.

PMID: 38532071 PMC: 11055680. DOI: 10.1038/s42255-024-01015-w.